LATAM MedTech Insights

This week, we dissect the critical new amendment to Brazil's RDC 657 software regulations, a move by ANVISA that specifically targets AI and machine learning devices. The update introduces complex new requirements for clinical validation, post-market changes, and cybersecurity, significantly raising the bar for market entry. We explore what these changes mean for MedTech manufacturers, why Brazil is becoming one of the most demanding markets for digital health, and how companies can adapt their strategies to succeed. **Case Study:** Imagine your AI-powered diagnostic software, already successful in Europe and the US, is ready for its Brazilian launch. Suddenly, ANVISA's new amendment...

This week, we dissect breaking news from Brazil. ANVISA, the national health regulatory agency, has just launched a new fast-track pilot program for AI-powered medical software. This move could slash market entry timelines in half, but it comes with a host of new, complex requirements that could trap unprepared companies. We explore the specific opportunities this creates for MedTech innovators in the diagnostic space and the hidden challenges in clinical data and cybersecurity compliance that lie beneath the surface. This is a must-listen for any company looking to capitalize on Brazil's push to become a digital health powerhouse. Case Study...

Brazil's ANVISA just launched a new fast-track approval process for AI medical software, a huge opportunity for MedTech innovators. However, this golden ticket comes with a major catch: a strict data localization law that could derail market entry plans for unprepared international companies. This episode of LATAM MedTech Insights unpacks the new resolution and explores the critical strategic decisions that foreign device manufacturers now face. We delve into the dual nature of this regulation. It is both a massive opportunity to accelerate entry into a booming market and a significant operational hurdle that demands a sophisticated, localized strategy. **Case In...

This week on LATAM MedTech Insights, we dissect the seismic shift in Brazil's regulatory landscape. Last week, ANVISA issued an unexpected technical note on clinical evaluation requirements under RDC 751, fundamentally altering the path to market for many international device manufacturers. We explore the end of the 'easy' equivalence route based on CE or FDA clearance and what this means for your technical dossier, budget, and timeline. This isn't just a minor update; it's a strategic challenge that redefines market entry into Latin America's largest economy. Imagine you're a US-based orthopedic company, weeks away from submitting your dossier to ANVISA, only...

Brazil's ANVISA just opened a fast-track approval process for AI medical devices, creating a huge opportunity for MedTech innovators. But this incredible speed comes with a hidden challenge: a new set of ultra-stringent cybersecurity regulations that are catching many companies off guard and threatening to derail their launch plans. Imagine a US-based scaleup, CardioVision AI, ready to enter Brazil with their FDA-cleared diagnostic software. They see ANVISA's new fast-track and are excited for a quick launch. But their team suddenly discovers the new rules demand a level of data encryption and mandatory local data hosting they hadn't prepared for. Their...

This week on LATAM MedTech Insights, we dissect the groundbreaking new regulations for AI-powered medical devices just announced by Brazil's ANVISA. This move positions Brazil at the forefront of digital health governance in Latin America, but it also creates a complex new landscape for manufacturers to navigate. We break down what these changes mean, from updated cybersecurity mandates to new requirements for algorithmic transparency. We also explore the immediate impact on MedTech innovators who are looking to enter the lucrative, yet challenging, Brazilian market. Imagine your company has a revolutionary AI diagnostic tool and you were on the verge of...

In this episode, we dissect the immediate impact of Brazil's new ANVISA resolution, RDC 848/2024. This isn't just another regulatory update; it's a fundamental shift in how Brazil evaluates the safety and performance of medical devices, with a sharp new focus on lifecycle risk management and cybersecurity. We explore how this change disrupts the conventional market entry strategy for international MedTech companies. A previously straightforward submission process now requires a new level of evidence, particularly for connected devices and Software as a Medical Device (SaMD), creating unforeseen delays and costs for those unprepared. **Key Questions Answered:** * Why is Brazil's RDC 848/2024 more...

This week, we dive into a game-changing regulatory shift in Latin America's largest MedTech market. Brazil's ANVISA has just launched a new "reliance pathway," promising to dramatically accelerate market access for high-risk medical devices that have already been approved by authorities like the US FDA. This could slash years off of registration timelines. In this episode, we unpack the reality behind the hype. We explore the massive opportunities this creates for international manufacturers and the critical details that could make or break a successful submission. Learn what "essentially identical" really means for your product and why local compliance is more...

Brazil just rewrote the rules for digital health. Last week, ANVISA published its new regulatory framework for Software as a Medical Device (SaMD), creating an urgent new landscape for MedTech companies. This update introduces a new risk classification system, expedited pathways for some devices, and significant new hurdles for high-risk AI and machine learning technologies. This episode of LATAM MedTech Insights unpacks the critical details of this regulatory shift. We explore the specific requirements that international companies must meet, including the complex pre-approval process for algorithm changes and the stringent new data privacy rules tied to Brazil's LGPD. For companies...

This week, we dissect a major regulatory shift in Brazil's MedTech landscape. ANVISA has just rolled out its new strategic framework for Software as a Medical Device (SaMD) and AI, aiming to align with global standards. But what does this mean for the innovators on the ground?. While harmonization promises safer and more effective digital health tools, the new requirements could inadvertently create significant barriers for local startups. This episode explores how the heightened demands for clinical data and cybersecurity might give large multinational corporations a distinct advantage in one of Latin America's biggest markets. **Case In Point:** Consider a...

In this episode of LATAM MedTech Insights, we dissect the breaking news from Brazil. In the final week of March 2026, ANVISA released a surprise guidance document for Software as a Medical Device (SaMD), creating immediate and significant new hurdles for foreign manufacturers. We explore the specific changes to clinical data requirements and cybersecurity protocols that have caught the industry off guard. This isn't just a minor update; it's a fundamental shift in how digital health products will be evaluated and approved in Latin America's largest market. We explain why your existing global data might suddenly be invalid and what this...

This episode of LATAM MedTech Insights dives into the immediate fallout from ANVISA's sudden enforcement of its Unique Device Identification (UDI) system in Brazil. We unpack the operational chaos this is causing for MedTech manufacturers who were unprepared for the complex data submission and labeling requirements. We explore how this regulatory shift is more than a bureaucratic hurdle. it represents a fundamental change in what it takes to access and succeed in Latin America's largest market. We discuss the critical role of the Brazil Registration Holder (BRH) and how a simple data mismatch can derail an entire product launch. A...

In this episode of LATAM MedTech Insights, we dissect the sudden and impactful new regulation from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). International manufacturers are now facing unprecedented requirements for localized clinical data and stringent cybersecurity protocols, effectively rewriting the rulebook for market access in Latin America's largest economy. We explore the immediate consequences of this regulatory shift, moving beyond the headlines to analyze the strategic and financial implications. We discuss why existing clinical data from bodies like the FDA or the EU may no longer be sufficient for ANVISA and what...

In this episode of LATAM MedTech Insights, we dissect the groundbreaking new regulation from Brazil's ANVISA, RDC 922/2026, which just rewrote the rules for AI-powered medical software. This isn't just an update; it's a seismic shift that introduces mandatory local clinical data requirements, impacting market access timelines and costs for foreign manufacturers. We explore the immediate consequences for MedTech innovators, especially those relying on existing FDA or CE Mark approvals. Learn what this increased scrutiny means for your product's classification, the validation process, and your overall launch strategy in Latin America's largest market. **Case In Point:** A promising US-based AI diagnostics...

In this episode, we dissect a sudden and critical regulatory update from Brazil's ANVISA that was issued just last week. The new instruction imposes stringent cybersecurity and data handling requirements on all Software as a Medical Device (SaMD) and connected devices, catching many international manufacturers off guard and putting existing market approvals at risk. We explore the specific technical and documentation changes now required, from mandatory penetration testing to new data localization rules. This shift forces companies to rethink their entire compliance and operational strategy for Latin America's largest market. A case in point: A successful foreign manufacturer of remote...

Brazil's medical device authority has just unveiled a new framework for AI technologies, signaling a gold rush for innovators in the region. This new resolution promises a clearer path to market for cutting-edge software as a medical device, opening doors to Latin America's largest healthcare economy. But hidden within this opportunity is a critical challenge that could stop foreign companies in their tracks. The regulation mandates strict adherence to Brazil's General Data Protection Law (LGPD), a complex and demanding data privacy standard. This episode of LATAM MedTech Insights unpacks the new AI resolution, exposing the hidden compliance traps and what...

In this episode, we dive into the landmark new resolution from Brazil’s Federal Council of Medicine (CFM) that creates a specific regulatory framework for Artificial Intelligence in medicine. This is a pivotal moment for digital health in Latin America, establishing new rules for physician oversight, data privacy, and the responsibilities of technology providers. We explore the immediate impact on MedTech and IVD manufacturers aiming to launch AI-powered solutions in the Brazilian market. This isn't just a guideline for doctors. it's a new set of requirements for the tools they use. We break down what this means for product design, te...

This week on LATAM MedTech Insights, we dive into the seismic shift in Brazil's digital health market. ANVISA just launched its 'Agiliza-IA' program, promising to approve AI-powered diagnostic software in a record 90 days. This could unlock one of the largest markets in Latin America for SaMD innovators. But there's a catch. While the speed is tempting, the program introduces formidable new barriers. Consider a European company with a market-leading AI tool. They're ready to enter Brazil, but now face an unexpected demand for clinical trials conducted exclusively on Brazilian patients. This single requirement could delay their entry by a year...

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just unveiled a new "Reliance" pathway, promising an incredible 80% reduction in review time for medical devices already approved by MDSAP authorities. This could dramatically accelerate market access for many international firms. However, this new shortcut comes with a critical catch. At the same time, ANVISA has implemented stricter, IMDRF-aligned standards for essential safety and performance requirements. This means the technical documentation bar has been raised significantly, potentially creating new hurdles even for experienced manufacturers. We break down the opportunity and the hidden challenge. We explore the case...

Brazil's MedTech landscape is shifting. A quiet but powerful new technical note from ANVISA has just redefined the rules for AI-powered medical devices, creating immediate hurdles for global manufacturers. This update directly links cybersecurity and data privacy to the core of the device approval process, impacting all new and pending registrations. In this episode, we dissect the three critical areas of this clarification, from new clinical data expectations to the now-mandatory Software Bill of Materials (SBOM). We explore how ANVISA is tightening its alignment with Brazil's General Data Protection Law (LGPD) and what it means for your technical dossier. This...

Last week, Mexico's regulatory body, COFEPRIS, enhanced its partnership with the U.S. FDA, launching a new phase of its fast-track program for medical devices. This creates an accelerated approval pathway for devices already cleared in the United States, representing a landmark shift in the region's regulatory landscape. This episode dissects the massive opportunity this presents, which can cut market entry timelines from years down to just months. We explore which devices qualify, the detailed submission requirements, and what "regulatory reliance" truly means for your quality and post-market surveillance strategy. **Burning Questions for This Episode:** * Which specific device categories are...

Brazil's medical device market is undergoing a seismic shift. The national regulator, ANVISA, has just released RDC 848/2024, a sweeping new resolution that redefines the essential safety and performance requirements for all medical devices and IVDs. This isn't just a simple update; it's a new paradigm that demands a total lifecycle approach to compliance and introduces stringent new rules for high-tech areas like software and cybersecurity. This episode breaks down exactly what this means for manufacturers, especially those from outside Latin America. We reveal the hidden hurdles that can derail your product launch and lead to costly delays. For example, a...

This week, we dive into a major regulatory shift in Brazil. ANVISA has just launched an exciting fast-track approval process for AI-powered medical software, creating a huge opportunity for MedTech innovators to enter Latin America's biggest market faster than ever before. But this new speed comes with a hidden challenge. The new pathway is tied to incredibly strict data privacy and cybersecurity rules based on Brazil's LGPD. These new requirements around data storage and patient consent are already creating significant hurdles, turning a golden opportunity into a complex compliance trap for unprepared companies. We explore a real-world case of a...

In this episode, we dissect a sudden, unannounced regulatory shift from Brazil's ANVISA that is impacting the global Software as a Medical Device (SaMD) industry. Last week, the agency mandated a new, complex cybersecurity audit for all SaMD products, to be conducted exclusively by a short list of local Brazilian firms. This surprise move creates a significant new hurdle for market access. We explore the immediate consequences of this decision, discussing the operational and financial strains it places on international MedTech companies aiming to enter or expand within Latin America's largest market. Imagine your product launch, years in the making...

This week, we dissect the groundbreaking new regulation from Brazil's ANVISA. A new fast-track approval pathway for AI and Machine Learning medical software promises to slash market entry timelines, opening the door for innovative diagnostic technologies to reach one of LATAM's biggest markets. However, a critical and complex clause lurks within the fine print: a strict data residency requirement. We explore how this 'data trap' creates significant operational and financial hurdles for foreign MedTech companies, potentially offsetting the benefits of the accelerated review process and reshaping market entry strategies for the entire region. Imagine you're a startup with a revolutionary...

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for manufacturers aiming to enter or remain in Latin America's largest market. We uncover the specific documentation now required and explain why your existing FDA or CE marking might not be enough. This episode delves into the real-world impact of these changes. Imagine your state-of-the-art health app, already successful in the U.S. and Europe, is suddenly halted at the Brazilian border. Your dossier is rejected for failing to...

This episode of LATAM MedTech Insights dives deep into the lingering challenges of Brazil's landmark medical device regulation, ANVISA RDC 751. Years after its implementation, we explore the real-world operational hurdles that international MedTech companies continue to face, moving beyond the basics to uncover the hidden complexities in risk classification, technical documentation, and post-market surveillance. We analyze the costly surprises that arise from device reclassification. For instance, a manufacturer of orthopedic implants saw their product up-classified from Class II to Class III, triggering unexpected requirements for extensive, local clinical data. This single issue delayed their market entry by over a year...

Brazil's MedTech market is undergoing a seismic regulatory shift. ANVISA, the national health surveillance agency, is rolling out a series of major updates, including the new RDC 848/2024, which redefines essential safety and performance requirements with a strong focus on lifecycle risk management and cybersecurity. This is creating a new, complex web of compliance for manufacturers. This episode of LATAM MedTech Insights unpacks the practical implications of these changes. We go beyond the headlines to explore the operational hurdles, such as the mandatory transition to a new digital certificate platform by 2025. We reveal the hidden pitfalls that are already causing submission...

This week, we dive into a sudden and critical regulatory update from Brazil's ANVISA that is sending ripples through the AI medical device community. A new technical clarification has redefined the rules for software-based devices, creating unexpected and costly new hurdles for foreign manufacturers trying to enter Latin America's biggest market. We explore the two main challenges this clarification presents: a new, strict requirement for clinical data from the Brazilian population, and complex cybersecurity documentation mandates that must be localized in Portuguese and aligned with local data laws. This episode breaks down what these changes mean on the ground and...

In this episode of LATAM MedTech Insights, we break down the critical new IVD regulation in Brazil, RDC 830/2023. This isn't just another update; it's a complete overhaul that aligns In-Vitro Diagnostic devices with the stringent framework of the general medical device regulation, RDC 751/2022, creating a new set of rules and unexpected hurdles for manufacturers. We uncover the hidden complexities within this harmonization effort, from reclassifying your product's risk level to meeting demands for more robust clinical evidence and local performance data. This shift signals ANVISA's move towards a more demanding and localized regulatory system, making prior foreign approvals less of...

Brazil just added a complex new layer to its AI MedTech regulations. Last week, the Federal Council of Medicine (CFM) issued Resolution 2,454, a framework that directly impacts how physicians can use AI tools. This isn't about device registration through ANVISA; it's about winning the trust and acceptance of the end-users—the doctors themselves. This episode dives deep into what this resolution means for foreign MedTech innovators. We explore how this new ethical and governance-focused oversight creates a dual-approval landscape where both regulatory bodies and medical associations hold the keys to market access. We break down the unwritten rules and hidden ch...

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for foreign manufacturers. We explore the specific documentation now required and what this means for anyone trying to enter Latin America's largest market. This move signals a major shift in the region's regulatory philosophy, moving away from simple adoption of global standards towards hyper-local requirements tied to national laws like the LGPD. We analyze the immediate impact on companies with pending applications, using a real-world example of a European...

This week, we dissect a game-changing announcement from Brazil's ANVISA: a new "fast-track" approval process for AI-powered medical devices. While it promises rapid market access, it hides significant challenges beneath the surface that could derail unprepared international companies. This episode explores how Brazil's stringent data privacy law, the LGPD, is interwoven into this new regulatory pathway. We reveal why your existing global compliance frameworks might be insufficient and what specific steps are necessary to successfully navigate this complex but promising opportunity in Latin America's largest MedTech market. **Case Study:** Learn from the missteps of a European AI-diagnostic firm that saw...

Last week, Brazil's regulatory agency, ANVISA, issued an unexpected technical guidance that reclassifies certain Software as a Medical Device (SaMD) products. This move has sent shockwaves through the digital health sector, pushing many devices that rely on predictive algorithms into higher-risk categories overnight, invalidating existing registrations. In this episode of LATAM MedTech Insights, we break down what this clarification means for manufacturers, the new clinical evidence required for compliance under RDC 751, and why this signals a major strategic shift in Brazil's approach to digital health regulation. We explore the immediate commercial impact and the long-term strategic adjustments companies must now...

This week on LATAM MedTech Insights, we dive into the significant new regulatory guidance from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). This update brings Brazil closer to global standards but introduces critical new challenges for foreign manufacturers in areas like risk classification, AI validation, and cybersecurity. We explore the immediate impact on MedTech companies aiming for the Brazilian market. For example, a US-based digital health firm was on the verge of submitting its product for approval. Now, they're confronting the painful reality that their AI algorithm's validation data is insufficient under the...

This week, we dive into a major regulatory shift in Brazil that just went live on March 1st, 2026. ANVISA's new Normative Instruction N°426/2026 activates the national UDI (Unique Device Identification) database, requiring manufacturers to submit detailed product data before entering the market. This episode breaks down the new requirements, the critical phased deadlines for different device classes, and the strategic implications for MedTech companies aiming to succeed in Latin America's largest market. We explore the hidden complexities, such as the absolute need for data equivalence between your ANVISA registration and your UDI submission. Consider the case of a cardiac stent m...

This episode of LATAM MedTech Insights, brought to you by Pure Global, dives into the landmark regulatory shift just implemented by Brazil's ANVISA. We unpack the new RDC 830/2023 resolution for In-Vitro Diagnostic (IVD) devices, a critical update that redefines market access and compliance in Latin America's largest market. We explore how this harmonization with global standards impacts everything from risk classification to technical documentation. More importantly, we reveal the new strategic 'reliance pathway' that could dramatically accelerate your product's journey to market. Imagine your high-risk diagnostic device, facing a potential year-long review, suddenly becoming eligible for an expedited process in...

A seismic regulatory shift is underway in Brazil, Latin America's biggest MedTech market. ANVISA's new Unique Device Identification (UDI) system, detailed in Normative Instruction 426/2026, is now being implemented. This isn't just a new labeling rule; it's a complex data management and submission challenge that could become a major barrier to market entry for unprepared device manufacturers. This episode breaks down exactly what the new requirements mean for your business. We go beyond the surface-level announcements to explore the practical, operational hurdles you will face. We discuss the critical importance of the SIUD database, the staggered compliance deadlines for different device...

Brazil's MedTech market just experienced a seismic shift. ANVISA, the national regulatory agency, has rolled out its new comprehensive framework, RDC 751, fundamentally changing the rules for medical device registration and market access. This move aligns Brazil closer than ever with international standards like the EU MDR. In this episode, we break down what this massive overhaul means for manufacturers. We dissect the new risk classification system, the updated submission pathways, and the critical changes to technical dossier requirements, providing a clear roadmap for anyone looking to enter or stay in Latin America's largest healthcare market. Imagine a MedTech scale-up from...

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA, RDC 989, which establishes a new fast-track approval pathway for AI-driven diagnostic software. This is a pivotal moment for the MedTech industry in Latin America, promising to accelerate innovation and market access. However, this opportunity comes with significant new hurdles. The regulation introduces complex requirements for predetermined change control plans, mandates the use of local Brazilian patient data for algorithm validation, and enforces stricter cybersecurity protocols. We explore the strategic implications for foreign and domestic manufacturers aiming to capitalize on this new landscape. A real-world example. a U.S.-based...